Clinical Trials Browser

Phase 2/3 × NETWORK × 90 days × Clear all

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

Lung Neoplasms